CANC Price Prediction, Tema Oncology ETF AI Recommendations

The most notable companies in this group are Merck & Co (NYSE:MRK), AstraZeneca PLC (NASDAQ:AZN), Regeneron Pharmaceuticals (NASDAQ:REGN), Bristol-Myers Squibb Co (NYSE:BMY), Gilead Sciences (NASDAQ:GILD), Moderna (NASDAQ:MRNA), Illumina (NASDAQ:ILMN), Incyte Corp (NASDAQ:INCY), Exact Sciences Corp (NASDAQ:EXAS), Exelixis (NASDAQ:EXEL).

The investment seeks to provide long-term growth. Under normal circumstances, the fund seeks to achieve its investment objective by investing at least 80% of its net assets, which include borrowings for investment purposes, in publicly listed companies that derive at least 50% of revenues from oncology. The fund is non-diversified.

The average market capitalization across the Tema Oncology ETF ETF is 26.35B. The market cap for tickers in the group ranges from 3.51M to 331.75B. MRK holds the highest valuation in this group at 331.75B. The lowest valued company is NOVN at 3.51M.

The average weekly price growth across all stocks in the Tema Oncology ETF ETF was 23%. For the same ETF, the average monthly price growth was 56%, and the average quarterly price growth was 86%. NUVL experienced the highest price growth at 20%, while MRNA experienced the biggest fall at -12%.

The average weekly volume growth across all stocks in the Tema Oncology ETF ETF was -8%. For the same stocks of the ETF, the average monthly volume growth was 24% and the average quarterly volume growth was 19%